# Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors

> **NCT03474289** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 134 (estimated)

## Conditions studied

- Tumor

## Interventions

- **DRUG:** SHR-1316

## Key facts

- **NCT ID:** NCT03474289
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-01
- **Primary completion:** 2019-01-30
- **Final completion:** 2019-10-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2018-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474289, "Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03474289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*